Regulus Therapeutics Inc (RGLS) 16.06 $RGLS
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 10.06 (+0.02), STEM: 1.02 (-0.01), RTRX: 10.12 (+0.24), RGLS: 16.06 (-0.25), SNY: 45.16 (-1.05), MNKD: 5.11 (-0.14)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.58 (-0.09), AMGN: 164.53 (-1.55), RGLS: 16.06 (-0.25), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), PVCT: 0.89 (unch), CANF: 3.49 (+0.03), DCTH: 1.27 (+0.03), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29)
Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference
PR Newswire - Wed Nov 26, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel on Wednesday, December 3, 2014 at 2:00 p.m. EST. The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of Regulus' website at www.regulusrx.com. A replay of the webcast will be archived on Regulus' website following the presentation date.
RGLS: 16.06 (-0.25)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.32 (+0.05), ISIS: 62.32 (+0.45), DRNA: 12.88 (+1.19), ALNY: 100.45 (+0.23), ARWR: 5.76 (-0.17), SRPT: 13.97 (-0.33), ALXN: 186.90 (-4.72), TKMR: 14.28 (+0.19), RGLS: 16.06 (-0.25)
European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST
GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
DexCom names Mark G. Foletta to board
M2 - Thu Nov 20, 5:38AM CST
Ambulatory glucose monitoring company DexCom (NasdaqGS
XCM) revealed on Wednesday the addition of Mark G. Foletta as its independent board member.
DXCM: 53.66 (-0.67), RGLS: 16.06 (-0.25)
Regulus To See Further Declines
Richard Pearson - Seeking Alpha - Wed Nov 19, 9:30AM CST
On October 22nd, Regulus Therapeutics (NASDAQ: RGLS ) released its " proof of concept " data for its Hep C drug RG-101. The stock price quickly soared from its prior level of $6-7 to as high as $25 (intra day) as enthusiasm for the drug ran...
ISIS: 62.32 (+0.45), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), RGLS: 16.06 (-0.25)
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 4.33 (+0.07), LXRX: 0.85 (-0.05), IMGN: 10.01 (unch), RGLS: 16.06 (-0.25), ARNA: 3.91 (-0.18)
DexCom Announces Appointment of Mark G. Foletta as Board Member
Business Wire - Wed Nov 19, 7:30AM CST
DexCom, Inc. (NASDAQ XCM) today announced the appointment of Mark G. Foletta as an independent Board member of the company.
DXCM: 53.66 (-0.67), RGLS: 16.06 (-0.25)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 62.32 (+0.45), A: 39.72 (-0.90), TKMR: 14.28 (+0.19), ILMN: 184.30 (-2.53), RGLS: 16.06 (-0.25), GSK: 42.42 (-0.93), HOLX: 25.85 (-0.52), GHDX: 32.13 (-0.53), NVS: 93.52 (-0.82)
Strong On High Relative Volume: Regulus Therapeutics (RGLS)
at The Street - Tue Nov 18, 9:01AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 16.06 (-0.25)
Critical Alerts For Zillow, Organovo, Regulus Therapeutics, JC Penney and FireEye Released By InvestorsObserver
PR Newswire - Mon Nov 17, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for Z, ONVO, RGLS, JCP and FEYE.
FEYE: 29.12 (-0.32), ONVO: 6.35 (+0.85), JCP: 6.38 (+0.29), RGLS: 16.06 (-0.25), Z: 117.89 (+0.82)
Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting
PR Newswire - Sat Nov 15, 5:00PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's (ASN) Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. Alport syndrome is a life-threatening, genetic kidney disease with no approved therapy, and currently, ACE (angiotensin-converting enzyme) inhibitors are emerging as standard of care to treat proteinuria, an indicator of chronic kidney disease (CKD) in these patients. Studies have shown that miR-21 plays a role in the progression of Alport syndrome and is up-regulated in mouse disease models, other renal fibrosis models and human CKD patients. These findings, and the new preclinical data presented at the ASN meeting, provide additional evidence that RG-012 may provide therapeutic benefit in the treatment of Alport syndrome.
RGLS: 16.06 (-0.25)
Regulus set for gap down on profit taking
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:22AM CST
RGLS: 16.06 (-0.25)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:10AM CST
MNK: 94.72 (-0.36), CYBR: 37.98 (+0.13), ZAZA: 1.46 (-0.13), FUEL: 14.85 (+0.89), ASTI: 1.20 (-0.03), RGLS: 16.06 (-0.25), SPWR: 23.06 (-0.41), DWA: 21.75 (+0.04), CIG: 4.90 (+0.03), AME: 48.59 (-1.05), JCP: 6.38 (+0.29), ICLD: 3.01 (-0.05), ALG: 47.27 (-0.53)
Regulus Therapeutics' (RGLS) CEO Kleanthis Xanthopoulos Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:15PM CST
RGLS: 16.06 (-0.25)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:36PM CST
CYBR: 37.98 (+0.13), DKS: 48.58 (+0.37), SAND: 2.95 (-0.10), XONE: 17.94 (-0.33), FUEL: 14.85 (+0.89), RGLS: 16.06 (-0.25), ACM: 29.40 (-0.12), NTAP: 40.69 (-1.50), BZH: 18.15 (-0.07), DY: 31.46 (-0.66)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 10.06 (+0.02), STEM: 1.02 (-0.01), RTRX: 10.12 (+0.24), RGLS: 16.06 (-0.25), SNY: 45.16 (-1.05), MNKD: 5.11 (-0.14)
Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.58 (-0.09), AMGN: 164.53 (-1.55), RGLS: 16.06 (-0.25), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), PVCT: 0.89 (unch), CANF: 3.49 (+0.03), DCTH: 1.27 (+0.03), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29)
Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference
PR Newswire - Wed Nov 26, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel on Wednesday, December 3, 2014 at 2:00 p.m. EST. The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of Regulus' website at www.regulusrx.com. A replay of the webcast will be archived on Regulus' website following the presentation date.
RGLS: 16.06 (-0.25)
Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.32 (+0.05), ISIS: 62.32 (+0.45), DRNA: 12.88 (+1.19), ALNY: 100.45 (+0.23), ARWR: 5.76 (-0.17), SRPT: 13.97 (-0.33), ALXN: 186.90 (-4.72), TKMR: 14.28 (+0.19), RGLS: 16.06 (-0.25)
European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST
GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
DexCom names Mark G. Foletta to board
M2 - Thu Nov 20, 5:38AM CST
Ambulatory glucose monitoring company DexCom (NasdaqGS
XCM) revealed on Wednesday the addition of Mark G. Foletta as its independent board member. DXCM: 53.66 (-0.67), RGLS: 16.06 (-0.25)
Regulus To See Further Declines
Richard Pearson - Seeking Alpha - Wed Nov 19, 9:30AM CST
On October 22nd, Regulus Therapeutics (NASDAQ: RGLS ) released its " proof of concept " data for its Hep C drug RG-101. The stock price quickly soared from its prior level of $6-7 to as high as $25 (intra day) as enthusiasm for the drug ran...
ISIS: 62.32 (+0.45), ALNY: 100.45 (+0.23), ACHN: 13.28 (-0.11), RGLS: 16.06 (-0.25)
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 4.33 (+0.07), LXRX: 0.85 (-0.05), IMGN: 10.01 (unch), RGLS: 16.06 (-0.25), ARNA: 3.91 (-0.18)
DexCom Announces Appointment of Mark G. Foletta as Board Member
Business Wire - Wed Nov 19, 7:30AM CST
DexCom, Inc. (NASDAQ
XCM) today announced the appointment of Mark G. Foletta as an independent Board member of the company. DXCM: 53.66 (-0.67), RGLS: 16.06 (-0.25)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 62.32 (+0.45), A: 39.72 (-0.90), TKMR: 14.28 (+0.19), ILMN: 184.30 (-2.53), RGLS: 16.06 (-0.25), GSK: 42.42 (-0.93), HOLX: 25.85 (-0.52), GHDX: 32.13 (-0.53), NVS: 93.52 (-0.82)
Strong On High Relative Volume: Regulus Therapeutics (RGLS)
at The Street - Tue Nov 18, 9:01AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 16.06 (-0.25)
Critical Alerts For Zillow, Organovo, Regulus Therapeutics, JC Penney and FireEye Released By InvestorsObserver
PR Newswire - Mon Nov 17, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for Z, ONVO, RGLS, JCP and FEYE.
FEYE: 29.12 (-0.32), ONVO: 6.35 (+0.85), JCP: 6.38 (+0.29), RGLS: 16.06 (-0.25), Z: 117.89 (+0.82)
Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting
PR Newswire - Sat Nov 15, 5:00PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's (ASN) Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. Alport syndrome is a life-threatening, genetic kidney disease with no approved therapy, and currently, ACE (angiotensin-converting enzyme) inhibitors are emerging as standard of care to treat proteinuria, an indicator of chronic kidney disease (CKD) in these patients. Studies have shown that miR-21 plays a role in the progression of Alport syndrome and is up-regulated in mouse disease models, other renal fibrosis models and human CKD patients. These findings, and the new preclinical data presented at the ASN meeting, provide additional evidence that RG-012 may provide therapeutic benefit in the treatment of Alport syndrome.
RGLS: 16.06 (-0.25)
Regulus set for gap down on profit taking
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:22AM CST
RGLS: 16.06 (-0.25)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:10AM CST
MNK: 94.72 (-0.36), CYBR: 37.98 (+0.13), ZAZA: 1.46 (-0.13), FUEL: 14.85 (+0.89), ASTI: 1.20 (-0.03), RGLS: 16.06 (-0.25), SPWR: 23.06 (-0.41), DWA: 21.75 (+0.04), CIG: 4.90 (+0.03), AME: 48.59 (-1.05), JCP: 6.38 (+0.29), ICLD: 3.01 (-0.05), ALG: 47.27 (-0.53)
Regulus Therapeutics' (RGLS) CEO Kleanthis Xanthopoulos Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:15PM CST
RGLS: 16.06 (-0.25)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:36PM CST
CYBR: 37.98 (+0.13), DKS: 48.58 (+0.37), SAND: 2.95 (-0.10), XONE: 17.94 (-0.33), FUEL: 14.85 (+0.89), RGLS: 16.06 (-0.25), ACM: 29.40 (-0.12), NTAP: 40.69 (-1.50), BZH: 18.15 (-0.07), DY: 31.46 (-0.66)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 104.43 (-2.29), GILD: 104.13 (-0.18), ACHN: 13.28 (-0.11), CNAT: 7.94 (+0.20), MRK: 57.72 (-1.62), LGND: 52.52 (-1.37), RGLS: 16.06 (-0.25), ABBV: 65.27 (-1.76), BMY: 58.75 (-0.93), ENTA: 43.23 (-3.20)
